A Phase II Study of Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) in Patients With Progressing Metastatic Neuroendocrine Carcinomas (NECs)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT06202066

Title field or adapter rule

{'original_value': 'A Phase II Study of Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) in Patients With Progressing Metastatic Neuroendocrine Carcinomas (NECs)', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:23.017217+00:00

Published At

2026-10-20T00:00:00+00:00

Record Updated At

2026-10-20

Source Retrieved At

2026-10-31T22:17:52.415050+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Digestive System Neuroendocrine Neoplasm", "Lung Neuroendocrine Neoplasm", "Malignant Solid Neoplasm", "Pancreatic Neuroendocrine Neoplasm"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-20", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT06202066"

protocolSection.identificationModule.officialTitle

"A Phase II Study of Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) in Patients With Progressing Metastatic Neuroendocrine Carcinomas (NECs)"

protocolSection.statusModule.overallStatus

"NOT_YET_RECRUITING"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Digestive System Neuroendocrine Neoplasm (protocolSection.conditionsModule.conditions)
• Lung Neuroendocrine Neoplasm (protocolSection.conditionsModule.conditions)
• Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)
• Pancreatic Neuroendocrine Neoplasm (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['(temozolomide, SurVaxM)'], 'description': 'Undergo blood sample collection', 'name': 'Biospecimen Collection', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['(temozolomide, SurVaxM)'], 'description': 'Undergo CT scan', 'name': 'Computed Tomography', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['(temozolomide, SurVaxM)'], 'description': 'Given SC', 'name': "Incomplete Freund''s Adjuvant", 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['(temozolomide, SurVaxM)'], 'description': 'Undergo MRI', 'name': 'Magnetic Resonance Imaging', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['(temozolomide, SurVaxM)'], 'description': 'Given SC', 'name': 'Sargramostim', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['(temozolomide, SurVaxM)'], 'description': 'Given SC', 'name': 'SVN53-67/M57-KLH Peptide Vaccine', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['(temozolomide, SurVaxM)'], 'description': 'Given PO', 'name': 'Temozolomide', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Temozolomide (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.